Related Experiment Video
Updated: Jul 10, 2026
06:19
Intracameral Injection in Rats with Low Risk of Adverse Effects
Published on: May 31, 2024
Bevacizumab in glaucoma: a review.
Parul Ichhpujani1, Aparna Ramasubramanian, Sushmita Kaushik
1Advanced Eye Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie
|November 21, 2007
Summary
Bevacizumab, an anti-VEGF therapy, shows potential in preventing scar tissue formation after glaucoma surgery. This review examines its clinical use in glaucoma filtering procedures to improve surgical outcomes.
Area of Science:
- Ophthalmology
- Vascular Biology
- Surgical Innovation
Background:
- Neovascularization is a complex process involving multiple growth factors.
- Vascular endothelial growth factor (VEGF) is crucial for ocular angiogenesis.
- Bevacizumab, a monoclonal antibody targeting VEGF, effectively reduces neovascularization.
Purpose of the Study:
- To review current clinical studies on the use of bevacizumab in glaucoma.
- To evaluate bevacizumab's efficacy in preventing bleb scarring after glaucoma filtering surgery.
Main Methods:
- Review of existing clinical studies and literature.
- Analysis of bevacizumab's mechanism of action in relation to wound healing.
Main Results:
- Bevacizumab has demonstrated promise in regressing neovascularization in various ocular conditions.
- Its application in glaucoma filtering surgery aims to retard bleb healing and maintain patency.
Conclusions:
- Bevacizumab is a potential therapeutic agent to enhance the success of glaucoma filtering surgery.
- Further clinical investigation is warranted to clarify its role in glaucoma management.
Related Concept Videos
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...